Angioedema 2 months after Administration of Rivaroxaban (Xarelto)
نویسندگان
چکیده
منابع مشابه
Xarelto, INN-Rivaroxaban
The application submitted is a complete dossier composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain test(s) or study(ies) Licensing status: The product was not licensed in any country at the time of submission of the application. • The CHMP opinion...
متن کاملHemi Orolingual Angioedema after tPA Administration for Acute Ischemic Stroke
INTRODUCTION As studies continue to demonstrate the efficacy of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke, the exclusion criteria continue to narrow, and the time-window continues to increase.1-3 The most dreaded adverse effect of tPA, hemorrhagic conversion of an ischemic stroke, is well known and well published.3 However, as an increasing number of patients are r...
متن کاملNovel oral anticoagulants for venous thromboembolism prophylaxis after total hip or knee replacement: an update on rivaroxaban (xarelto).
IntroductIon In 2005, approximately 285,000 individuals underwent total hip replacement (THR) procedures, and approximately 523,000 individuals had total knee replacement (TKR) procedures in the U.S.1 As the population ages, it is estimated that by 2030 the demand for these surgeries will increase, and the numbers are expected to grow to 572,000 THR procedures and 3,480,000 TKR procedures annua...
متن کاملCorrelation between rivaroxaban (Xarelto) plasma activity, patient clinical variables and outcomes in a South African centre.
BACKGROUND Low-molecular-weight heparin and vitamin K antagonists such as warfarin are the gold standard for prohylaxis and treatment of venous thromboembolic disease (VTED). Direct oral anticoagulants (DOACs) result in predictable anticoagulation with significantly reduced inter- and intra-patient variability. DOAC absorption is rapid, with a short half-life and relatively few drug interaction...
متن کاملRivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor.
238 P&T® • May 2009 • Vol. 34 No. 5 INTRODUCTION Thromboembolic disease is associated with significant mortality and morbidity, especially in hospitalized patients. Without thromboprophylaxis, the risk of deep-vein thrombosis (DVT) in hospitalized patients is 10% to 40% in medical and general surgical patients and 40% to 60% in patients undergoing orthopedic surgery. Adverse consequences of unr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Case Reports
سال: 2017
ISSN: 2165-7920
DOI: 10.4172/2165-7920.10001059